ScottSimonTykodiMDPhD

Associate Professor, Division of Medical Oncology, University of Washington Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center

Join to view full profile

Dr. Tykodi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tykodi's full profile

Already have an account?

Office
Seattle Cancer Care Alliance
825 Eastlake Avenue, E
Seattle, WA 98109
Phone+1 206-606-2015

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2000 - 2003
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1997 - 2000
Washington University in St. Louis School of MedicineClass of 1997

Certifications & Licensure

WA State Medical License 2000 - 2027
American Board of Internal Medicine Medical Oncology

Clinical Trials

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer Start of enrollment: 2018 Aug 28
Terminated
Phase 1

Publications & Presentations

PubMed

Genetic and Iatrogenic Defects in Peripheral Tolerance Associated with Anti-Nephrin Antibody-Associated Minimal Change Disease.
J Ashley Jefferson, Karin Chen, Sangeeta Hingorani, A Bilal Malik, Scott S Tykodi
Glomerular Diseases. 2025-01-09
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.
Toni K Choueiri, Jaime R Merchan, Robert Figlin, David F McDermott, Edward Arrowsmith
The Lancet. Oncology. 2025-01-01
Belzutifan for the treatment of renal cell carcinoma.
Xiancheng Wu, David Lazris, Risa Wong, Scott S Tykodi
Therapeutic Advances in Medical Oncology. 2025-01-01

Lectures

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

ASCO GU 2021: Nivolumab plus Ipilimumab in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma (nccRCC): Safety and Efficacy from CheckMate 920February 13th, 2021
Vaccinia Virus and Immune Checkpoint Inhibitors: A Viable Combination in Advanced RCC?May 27th, 2020
ASCO Annual Meeting to Highlight Clinical Oncology Findings from Seattle Cancer Care Alliance (SCCA)May 21st, 2020
Join now to see all